Floatz logo

ubt251

Chronic Kidney Disease

The United Bio-Technology (Hengqin) Co., Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Chronic Kidney Disease cohort.

Asset / SponsorPhaseRating
SODIUM FERRIC GLUCONATE
Watson Pharmaceuticals
Phase 4BBB
IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Watson Pharmaceuticals
Phase 4BBB
Semaglutide
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Plavix
Hospital Alemão Oswaldo Cruz
Phase 4BB
Acetylsalicylic Acid
Hospital Alemão Oswaldo Cruz
Phase 4BB

View all 50 →

Same molecule, other indications

ubt251 is also rated in:

obesity disorderDormant
BB
Indicative ·
64 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
CCC
Indicative ·
53 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →